Claims for Patent: 7,674,470

Summary for Patent: 7,674,470

Title:	Recombinant toxin fragments
Abstract:	Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain H.sub.N portion or a fragment or a variant thereof, wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated H.sub.C thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell surface receptors to which native clostridial neurotoxin binds. Antibodies that bind to the polypeptides, and compositions comprising these antibodies, are also provided, as are DNA vaccines comprising polynucleotides that encode these polypeptides. The antigenic and antibody compositions, and the DNA vaccine compositions, can be used in methods of immunising against, or treating, clostridial neurotoxin poisoning in a subject by administering to that subject a therapeutically effective amount of the composition.
Inventor(s):	Shone; Charles Clifford (Salisbury, GB), Quinn; Conrad Padraig (Lilburn, GA), Foster; Keith Alan (Salisbury, GB), Chaddock; John (Salisbury, GB), Marks; Philip (Salisbury, GB), Sutton; J. Mark (Salisbury, GB), Stancombe; Patrick (Salisbury, GB), Wayne; Jonathan (Salisbury, GB)
Assignee:	Health Protection Agency (Salisbury, GB) Syntaxin Limited (Salisbury, GB)
Application Number:	11/077,550
Patent Claims:	1. An antigenic composition comprising a single chain polypeptide comprising first and second domains, wherein: said first domain is a clostridial neurotoxin light chain or a variant thereof, or a fragment of said light chain or variant wherein said variant or fragment has a common antigenic cross-reactivity to said clostridial neurotoxin light chain; and said second domain is a clostridial neurotoxin heavy chain H.sub.N portion or a variant thereof, or a fragment of said heavy chain H.sub.N portion or variant wherein said variant or fragment has a common antigenic cross-reactivity to said clostridial neurotoxin heavy chain H.sub.N portion; and wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated H.sub.C thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell surface receptors to which native clostridial neurotoxin binds. 2. An antigenic composition according to claim 1, wherein said clostridial neurotoxin light chain is a botulinum neurotoxin light chain. 3. An antigenic composition according to claim 1, wherein said clostridial toxin light chain is a tetanus neurotoxin light chain. 4. An antigenic composition according to claim 1, wherein said clostridial neurotoxin heavy chain is a botulinum neurotoxin heavy chain. 5. An antigenic composition according to claim 1, wherein said clostridial toxin heavy chain is a tetanus neurotoxin heavy chain. 6. An antigenic composition according to claim 1, wherein said second domain is a clostridial neurotoxin heavy chain H.sub.N portion. 7. An antigenic composition according to claim 1, wherein the second domain lacks a C-terminal part of a clostridial neurotoxin heavy chain designated H.sub.C, thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell surface receptors to which native clostridial neurotoxin binds. 8. An antigenic composition according to claim 1, wherein one or both of said clostridial neurotoxin light chain and said clostridial neurotoxin heavy chain is a botulinum neurotoxin type A chain. 9. An antigenic composition according to claim 8, wherein the botulinum toxin type A light chain has at residue 2 a glutamate, at residue 26 a lysine and at residue 27 a tyrosine. 10. An antigenic composition according to claim 1, wherein the second domain comprises the 423 N-terminal amino acids of botulinum toxin type A heavy chain. 11. An antigenic composition according to claim 1, wherein one or both of said clostridial neurotoxin light chain and said clostridial neurotoxin heavy chain is a botulinum neurotoxin type B chain. 12. An antigenic composition according to claim 1, wherein the second domain comprises the 107 N-terminal amino acids of a botulinum toxin type B heavy chain. 13. An antigenic composition according to claim 1, wherein the second domain comprises the 417 N-terminal amino acids of botulinum toxin type B heavy chain. 14. An antigenic composition according to claim 1, wherein the clostridial neurotoxin light chain is a botulinum toxin type B light chain, and the second domain comprises the 417 N-terminal amino acids of a botulinum toxin type B heavy chain. 15. An antigenic composition according to claim 1, wherein one or both of said clostridial neurotoxin light chain and said clostridial neurotoxin heavy chain is a tetanus toxin chain. 16. An antigenic composition according to claim 1, wherein the second domain comprises the 422 N-terminal amino acids of tetanus heavy chain. 17. An antigenic composition according to claim 1, wherein the second domain comprises the 100 N-terminal amino acids of a clostridial neurotoxin heavy chain. 18. An antigenic composition according to claim 16 lacking a portion designated H.sub.C of a clostridial neurotoxin heavy chain. 19. An antigenic composition according to claim 17 lacking a portion designated H.sub.C of a clostridial neurotoxin heavy chain. 20. An antigenic composition according to claim 1 comprising a site for cleavage by a proteolytic enzyme. 21. An antigenic composition according to claim 20, wherein the cleavage site is not present in a native clostridial neurotoxin. 22. An antigenic composition according to claim 20, wherein the site for cleavage allows proteolytic cleavage of the first and second domains. 23. An antigenic composition according to claim 20 produced by a process comprising (a) inserting a first nucleic acid sequence encoding said cleavage site into a second nucleic acid sequence encoding the single chain polypeptide according to claim 1 and (b) expressing said first and second nucleic sequences to obtain said single chain polypeptide. 24. The antigenic composition of claim 1, wherein said single chain polypeptide is selected from the group consisting of: SEQ ID Nos. [2, 4, 6, 10, 12, 16, 20, 22, 24, 26, 30, 32, 34, 36, 38, 60, 62, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86,] 88, [90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114,116, 118, 120, 122,] 124, [126, 128, 130, 132,] 143, [145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167,] 169, [171, 173, 175, 177] and 179. 25. An antigenic composition comprising a single chain polypeptide encoded by a nucleic acid selected from the group consisting of SEQ ID Nos. [1, 3, 5, 9, 11, 13, 15, 19, 21, 23, 25, 27, 28, 29, 31, 33, 35, 37, 59, 61, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85,] 87, [89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121,] 123, [125, 127, 129, 131, 133, 135, 136,] 142, [144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164,] 168, [170, 172, 174, 176,] and 178. 26. A method of immunising against clostridial neurotoxin poisoning in a subject comprising administering to said subject a therapeutically effective amount of a composition according to claim 1. 27. An antigenic composition according to claim 1, wherein said variant of a light chain, or said fragment of said light chain or variant, has a common antigenic cross-reactivity to said light chain in an assay selected from: 1) a protection assay involving direct challenge of previously vaccinated animals with clostridial neurotoxin; and 2) an assay of the neutralising capability of the anti-sera obtained in response to exposure of an animal to said antigenic composition. 28. An antigenic composition according to claim 1, wherein said variant of a heavy chain H.sub.N portion, or said fragment of said heavy chain H.sub.N portion or variant, has a common antigenic cross-reactivity to said heavy chain H.sub.N portion in an assay selected from: 1) a protection assay involving direct challenge of previously vaccinated animals with clostridial neurotoxin; and 2) an assay of the neutralising capability of the anti-sera obtained in response to exposure of an animal to said antigenic composition. 29. An antigenic composition comprising a single chain polypeptide comprising first and second domains, wherein: said first domain is a clostridial neurotoxin light chain or a variant thereof, or a fragment of said light chain or variant wherein said fragment or variant has a common antigenic cross-reactivity to said clostridial neurotoxin light chain in an assay selected from: 1) a protection assay involving direct challenge of previously vaccinated animals with clostridial neurotoxin; and 2) an assay of the neutralising capability of the anti-sera obtained in response to exposure of an animal to said antigenic composition; and said second domain is a clostridial neurotoxin heavy chain H.sub.N portion or a variant thereof, or a fragment of said heavy chain H.sub.N portion or variant wherein said variant or fragment has a common antigenic cross-reactivity to said clostridial neurotoxin heavy chain H.sub.N portion; and wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated H.sub.C thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell surface receptors to which native clostridial neurotoxin binds. 30. An antigenic composition comprising a single chain polypeptide comprising first and second domains, wherein: said first domain is a clostridial neurotoxin light chain or a variant thereof, or a fragment of said light chain or variant wherein said fragment or variant has a common antigenic cross-reactivity to said clostridial neurotoxin light chain; and said second domain is a clostridial neurotoxin heavy chain H.sub.N portion or a variant thereof, or a fragment of said heavy chain H.sub.N portion or variant wherein said variant or fragment has a common antigenic cross-reactivity to said clostridial neurotoxin heavy chain H.sub.N portion in an assay selected from: 1) a protection assay involving direct challenge of previously vaccinated animals with clostridial neurotoxin; and 2) an assay of the neutralising capability of the anti-sera obtained in response to exposure of an animal to said antigenic composition; and wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated H.sub.C thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell surface receptors to which native clostridial neurotoxin binds.

Details for Patent 7,674,470

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2016-08-23